Buy 25N-NBOMe for sale online from USA vendor
Table of Contents
- Overview of 25N-NBOMe
- Chemistry
- Chemical Background
- Discovery
- Pharmacology
- Receptor Interaction
- Lack of Research
- Effects
- Subjective Effects
- Physical Effects
- Visual Effects
- Cognitive Effects
- Auditory Effects
- Multi-Sensory Effects
- Transpersonal Effects
- Experience Reports
- Subjective Effects
- Dosage
- Safety and Risks
- Toxicity and Harm Potential
- Tolerance and Addiction Potential
- Overdose
- Dangerous Interactions
- Legal Status
- International Legal Status
Introduction to 25N-NBOMe
25N-NBOMe, also known as 2C-N-NBOMe, NBOMe-2C-N, and colloquially referred to as N-Bomb (a term used broadly for the entire 25x-NBOMe family), is a novel psychedelic substance. It belongs to the phenethylamine chemical class and produces stimulating psychedelic effects when administered.
Chemical Background
The name 25N-NBOMe is shorthand for 2C-N-NBOMe, indicating it is a derivative of the phenethylamine psychedelic 2C-N. This substance was first discovered in 2004 by Ralf Heim at the Free University of Berlin. It was later investigated by a research team at Purdue University, led by David E. Nichols.
Pharmacology and Effects
Duration and Dosage
25N-NBOMe has a notably shorter duration compared to other substances in the 25x-NBOMe series. The total duration of its effects is approximately 6 hours, with a peak duration of about 2 hours. It is moderately active at a dose of one milligram, and a dose of two milligrams can induce a strong to heavy psychedelic experience.
Potency Comparison
When compared to more popular NBOMe compounds such as 25B-NBOMe, 25I-NBOMe, and 25C-NBOMe, 25N-NBOMe is considerably less potent. The aforementioned compounds produce strong effects at doses above 1mg, whereas 25N-NBOMe requires a slightly higher dose for similar effects.
Administration
NBOMe compounds, including 25N-NBOMe, are not orally active. They must be administered sublingually. This involves placing the substance under the tongue and holding it in the mouth to allow absorption over a period of 15-25 minutes.
History and Usage
Human Use
Before 2010, 25N-NBOMe had no documented history of human use. It emerged in the market as a designer drug sold online, marking the beginning of its human application.
Safety and Risks
Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25N-NBOMe in humans. Similar compounds in the 25x-NBOMe series have been linked to deaths and hospitalizations. The substance is known for its highly sensitive dose-response and unpredictable effects, making it challenging to use safely.
Harm Reduction
Due to the potential risks and lack of comprehensive understanding, it is highly advised to approach 25N-NBOMe with caution. Employing harm reduction practices is crucial if choosing to use this poorly understood psychedelic substance.
Chemical Background
The name 25N-NBOMe is shorthand for 2C-N-NBOMe, indicating it is a derivative of the phenethylamine psychedelic 2C-N. This substance was first discovered in 2004 by Ralf Heim at the Free University of Berlin. It was later investigated by a research team at Purdue University, led by David E. Nichols.
Pharmacology and Effects
Duration and Dosage
25N-NBOMe has a notably shorter duration compared to other substances in the 25x-NBOMe series. The total duration of its effects is approximately 6 hours, with a peak duration of about 2 hours. It is moderately active at a dose of one milligram, and a dose of two milligrams can induce a strong to heavy psychedelic experience.
Dosage Guidelines
- Threshold: < 100 µg
- Light: 100 - 300 µg
- Common: 300 - 800 µg
- Strong: 800 - 1300 µg
- Heavy: > 1300 µg
It is important to note that the NBOMe series can be fatal at heavy doses.
Potency Comparison
When compared to more popular NBOMe compounds such as 25B-NBOMe, 25I-NBOMe, and 25C-NBOMe, 25N-NBOMe is considerably less potent. The aforementioned compounds produce strong effects at doses above 1mg, whereas 25N-NBOMe requires a slightly higher dose for similar effects.
Administration
NBOMe compounds, including 25N-NBOMe, are not orally active. They must be administered sublingually. This involves placing the substance under the tongue and holding it in the mouth to allow absorption over a period of 15-25 minutes.
History and Usage
Human Use
Before 2010, 25N-NBOMe had no documented history of human use. It emerged in the market as a designer drug sold online, marking the beginning of its human application.
Safety and Risks
Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25N-NBOMe in humans. Similar compounds in the 25x-NBOMe series have been linked to deaths and hospitalizations. The substance is known for its highly sensitive dose-response and unpredictable effects, making it challenging to use safely.
Harm Reduction
Due to the potential risks and lack of comprehensive understanding, it is highly advised to approach 25N-NBOMe with caution. Employing harm reduction practices is crucial if choosing to use this poorly understood psychedelic substance.
Chemistry
Chemical Background
25N-NBOMe or 2C-N-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as 2C-N. It is a substituted phenethylamine with methoxy groups (CH3O-) attached to carbons R2 and R5, as well as a nitro group (NO2-) attached to carbon R4. It differs from 2C-N structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group. This NBOMe addition contains a methoxy ether (CH3O-) bound to a benzene ring at R2.
Discovery
This substance was first discovered in 2004 by Ralf Heim at the Free University of Berlin and was later investigated by a research team at Purdue University, led by David E. Nichols.
Pharmacology
Receptor Interaction
25N-NBOMe likely has efficacy at the 5-HT2A receptor, where it is assumed to act as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Lack of Research
There is insufficient scientific research to determine this compound's true nature, as the pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but only in anecdotal reports.
Effects
Subjective Effects
The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. These effects may not occur in a predictable or reliable manner. Higher doses are more liable to induce the full spectrum of effects, while adverse effects become increasingly likely.
Physical Effects
- Stimulation: Typically very energetic and stimulating, but controllable for most users. Some may experience uncontrollable stimulation, resulting in bodily shakes and teeth grinding.
- Perception of Bodily Lightness: Users often feel extremely light, sometimes to the point of total weightlessness.
- Spontaneous Physical Sensations: Mild, euphoric tingling sensations that can become more pronounced with higher doses.
- Physical Euphoria
- Tactile Enhancement
- Bodily Control Enhancement: When combined with stimulation, this manifests as a strong drive to partake in physical activities.
- Mouth Numbing: A strong, unpleasant metallic chemical taste and numbness in the mouth immediately after sublingual absorption.
- Abnormal Heartbeat
- Increased Heart Rate
- Increased Blood Pressure
- Muscle Contractions, Cramps, and Tension
- Gustatory Hallucinations
- Nausea: Especially during the come-up, subsiding over the peak.
- Appetite Suppression
- Runny Nose
- Stomach Cramps
- Dehydration and Dry Mouth
- Difficulty Urinating or Frequent Urination
- Restless Legs
- Pupil Dilation
- Headaches
- Seizures
Visual Effects
- Enhancements: Visual acuity, color enhancement, pattern recognition.
- Distortions: Drifting, melting, flowing, breathing, and morphing effects. Highly detailed, slow, and smooth in motion.
- Geometry: Algorithmic, intricate, fine, structured, colorful, glossy, and mostly rounded visual geometry.
- Hallucinatory States: Transformations and internal hallucinations, including autonomous entities, settings, and scenarios.
Cognitive Effects
- Analysis Enhancement
- Thought Acceleration and Deceleration
- Conceptual Thinking
- Anxiety and Paranoia
- Empathy, Affection, and Sociability Enhancement
- Memory Suppression
- Ego Death
- Amnesia
- Novelty Enhancement
- Immersion Enhancement
- Emotion Enhancement
- Increased Sense of Humor
- Laughter Fits
- Increased Music Appreciation
- Personal Bias Suppression
- Increased Libido
- Time Distortion
- Wakefulness
Auditory Effects
- Enhancements
- Distortions
- Hallucinations
Multi-Sensory Effects
- Dosage Independent Intensity
- Synaesthesia
Transpersonal Effects
- Existential Self-Realization
- Unity and Interconnectedness
Experience Reports
There are currently no anecdotal reports which describe the effects of this compound within the experience index. Additional experience reports can be found in the Erowid Experience Vaults.
Dosage
- Threshold: < 100 µg
- Light: 100 - 300 µg
- Common: 300 - 800 µg
- Strong: 800 - 1300 µg
- Heavy: > 1300 µg
The NBOMe series can be fatal at heavy doses.
Safety and Risks
Toxicity and Harm Potential
The toxicity and long-term health effects of recreational 25N-NBOMe use have not been studied in any scientific context, and the exact toxic dosage is unknown. Users should be cautious, as ingesting 2mg+ of NBOMe series chemicals has proven fatal in some cases. Although there are no reported deaths caused by 25N-NBOMe at this time, it is a rare research chemical with very little history of human usage and is therefore potentially fatal at heavy dosages.
Tolerance and Addiction Potential
25N-NBOMe is not habit-forming, and the desire to use it can decrease with use. Tolerance to its effects builds almost immediately after ingestion, reducing to half after 3 days and back to baseline in 7 days. It presents cross-tolerance with all psychedelics.
Overdose
The margin between a normal and an overdose of NBOMe compounds is extremely small. Dangerous side effects may appear when exceeding 1000 µg and can be potentially lethal at around 2000 µg for sensitive individuals. Overdose effects include dangerously high heart rate, blood pressure, hyperthermia, vasoconstriction, confusion, delusions, panic attacks, aggressive behavior, numbness, pain, amnesia, and seizures.
Dangerous Interactions
Many psychoactive substances can become dangerous when combined with NBOMe compounds. Known dangerous interactions include:
- 2C-T-X Phenethylamines
- 5-MeO Tryptamines
- Amphetamines
- Caffeine
- Cannabis
- Cocaine
- DOx
- DXM
- Lithium
- MAOIs
- MDMA
- MXE
- Tramadol
Legal Status
International Legal Status
- Austria: Illegal under NPSG.
- Brazil: Illegal under Portaria SVS/MS nº 344.
- Germany: Controlled under Anlage I BtMG as of June 9, 2016.
- Latvia: Schedule I controlled substance.
- Switzerland: Controlled under Verzeichnis E.
- United Kingdom: Class A drug under the N-benzylphenethylamine catch-all clause.
- United States: Unscheduled, but may be considered an analogue of 2C-N, making it potentially prosecutable under the Federal Analogue Act.
FAQ
What is 25N-NBOMe?
25N-NBOMe, also known as 2C-N-NBOMe, is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic 2C-N. It produces stimulating psychedelic effects and belongs to the phenethylamine chemical class.
What are the chemical properties of 25N-NBOMe?
25N-NBOMe has methoxy groups attached to carbons R2 and R5, and a nitro group attached to carbon R4. It differs from 2C-N by a substitution on the amine with a 2-methoxybenzyl group.
How does 25N-NBOMe interact with the brain?
It likely has efficacy at the 5-HT2A receptor and acts as a partial agonist, but its pharmacological properties are not well understood due to a lack of scientific research.
What are the physical effects of 25N-NBOMe?
Physical effects can include stimulation, perception of bodily lightness, spontaneous physical sensations, physical euphoria, tactile enhancement, mouth numbing, increased heart rate, and more.
What are the visual effects of 25N-NBOMe?
Visual effects can include visual acuity enhancement, color enhancement, pattern recognition enhancement, and various visual distortions such as drifting, melting, and symmetrical texture repetition.
What are the cognitive effects of 25N-NBOMe?
Cognitive effects can include analysis enhancement, thought acceleration and deceleration, conceptual thinking, anxiety and paranoia, empathy enhancement, memory suppression, ego death, and more.
What is the recommended dosage for 25N-NBOMe?
- Threshold: < 100 µg
- Light: 100 - 300 µg
- Common: 300 - 800 µg
- Strong: 800 - 1300 µg
- Heavy: > 1300 µg
What are the risks associated with 25N-NBOMe?
Risks include potential toxicity, overdose, dangerous side effects, and the unpredictability of effects. It is crucial to use harm reduction practices.
What is the legal status of 25N-NBOMe?
25N-NBOMe is illegal in many countries, including Austria, Brazil, Germany, Latvia, Switzerland, the United Kingdom, and may be considered an analogue of 2C-N in the United States.
What should be done in case of an overdose?
In case of an overdose, seek immediate medical attention. Symptoms can include dangerously high heart rate, blood pressure, hyperthermia, vasoconstriction, confusion, delusions, panic attacks, aggressive behavior, numbness, pain, amnesia, and seizures.
Can 25N-NBOMe be mixed with other substances?
Mixing 25N-NBOMe with other psychoactive substances is generally not advised due to the unpredictable nature of its interactions, which can become dangerous or life-threatening.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics